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Abstract Regulation of p85K phosphatidylinositol-3-kinase
(p85KPI-3K) expression by peroxisome proliferator-activated
receptor (PPAR) activators was studied in human skeletal
muscle cells. Activation of PPARQ or PPARL did not modify the
expression of p85KPI-3K. In contrast, activation of PPARK
increased p85KPI-3K mRNA. This effect was potentiated by 9-
cis-retinoic acid, an activator of RXR. Up-regulation of p85KPI-
3K gene expression resulted in a rise in p85KPI-3K protein level
and in an increase in insulin-induced PI3-kinase activity.
According to the role of p85KPI-3K in insulin action, these
results suggest that drugs with dual action on both PPARQ and
PPARK can be of interest for the treatment of insulin
resistance. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The peroxisome proliferator-activated receptors (PPARs)
are members of the nuclear receptor superfamily. Three di¡er-
ent PPAR genes have been characterized that give rise to four
distinct proteins (K, L, Q1 and Q2) [1,2]. PPARQ1 and Q2 are
generated from the same gene by alternative promoter usage
and mRNA splicing [3]. All PPARs heterodimerize with the 9-
cis-retinoic acid (9-cis-RA) receptor (RXR) [4] and change the
transcription rate of their target genes after binding to speci¢c
peroxisome proliferator-responsive elements (PPREs) [1,2].
PPARK is preferentially expressed in the liver [1,2,5,6], but
signi¢cant levels of the protein have been also found in skel-
etal muscle, kidney and endothelial cells [7]. PPARK is mainly
involved in the regulation of fatty acid oxidation, lipoprotein
metabolism and cellular fatty acid uptake [1,2]. PPARL (also
designated PPARN or NUC1) seems to be ubiquitously ex-
pressed [5,6] and its functions are still largely unknown. In
contrast, PPARQ is highly expressed in adipose tissue where it
is known to play a critical role in adipocyte di¡erentiation and
in fat deposition [8,9]. PPARQ1, however, is also expressed at
a signi¢cant level in other cells and tissues, like in colon [6], in
epithelial cells of the intestinal tract [10] or in macrophages
[11]. In addition, PPARQ1 mRNA [6,12] and protein [12] can
be detected in skeletal muscle, although the level of expression
was several fold lower than in the adipose tissue. In contrast,
PPARQ2 is expressed almost exclusively in adipocytes [6].
All PPARs are activated by naturally occurring fatty acids
or their derivatives [1,2,13^15] and by several synthetic com-
pounds [14^16]. Among them, the thiazolidinediones are a
new class of oral antidiabetic agents that reduce blood glu-
cose, insulin and triglyceride concentrations and increase in-
sulin sensitivity in animal models and in type-2 (non-insulin-
dependent) diabetic patients [17,18]. Thiazolidinediones are
high a⁄nity ligands of PPARQ, but the mechanism by which
activation of PPARQ results in an improvement of insulin
action is still largely unknown [8,9]. Proposed mechanisms
involve PPARQ-induced di¡erentiation of small insulin sensi-
tive fat cells, higher rate of fatty acids trapping by adipocytes,
or the reduction of adipocytokine expression [9]. In addition,
we have recently found that activation of PPARQ by Rosigli-
tazone can increase insulin signaling in human adipocytes by
inducing the expression of the p85K-regulatory subunit of
phosphatidylinositol-3-kinase (p85KPI-3K) [19,20] and by in-
creasing insulin-induced PI-3K and protein kinase B (PKB)
activities [20]. Because the PI-3K/PKB signaling pathway is
involved is almost all the metabolic e¡ects of insulin, notably
the translocation of glucose transporters [21]. It was tempting
to speculate that the observed up-regulation of p85KPI-3K
expression by Rosiglitazone [19,20] could participate in an
improvement of glucose uptake. However, the contribution
of adipose tissue to whole-body glucose uptake is low and it
is well recognized that skeletal muscles mainly contribute to
insulin resistance in vivo [22]. Because a signi¢cant expression
of PPARQ protein has been recently reported in human muscle
[12], we aimed to verify whether the e¡ect of Rosiglitazone on
p85KPI-3K expression found in adipose tissue also takes place
in skeletal muscle. For this purpose, we have investigated the
regulation of p85KPI-3K gene expression by PPAR activators
in human skeletal muscle cells in primary culture.
2. Materials and methods
2.1. Products
Rosiglitazone was kindly provided by SmithKline Beecham Phar-
maceuticals (Harlow, UK). The PPARL agonist L-165041 was a gift
from Drs. J. Berger and D. Moller from Merck and Co., Inc. (Rah-
way, NJ, USA). Wy-14643 were obtained from Biomol Research Lab-
oratories (Plymouth Meeting, PA, USA). All fatty acids and other
drugs were obtained from either Sigma (L’isle d’Abeau, France) or
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Biomol Research Laboratories. Culture media were from Life Tech-
nologies (Cergy Pontoise, France) or from Biomedia (Boussens,
France).
2.2. Primary culture of human skeletal muscle cells
Biopsies of the lumbar mass (erector spinae) muscle (about 1 g)
were taken, with the consent of the patient, during surgical procedure.
The experimental protocol was approved by the Ethics Committee of
Lyon Hospitals. In the present study, biopsies were taken from
healthy subjects (three men, three women, age = 49 þ 5 years, body
mass index ranging from 24 to 31 kg/m2) with no familial or personal
history of diabetes or dyslipidemia. The satellite cells were isolated
from the muscle biopsy by trypsin digestion and were grown as pre-
viously described in detail [23]. Con£uent myoblasts were allowed to
di¡erentiate into myotubes and were always used 12 to 16 days after
induction of the di¡erentiation process [23].
2.3. Quanti¢cation of p85KPI-3K mRNA
Total RNA was prepared using the RNeasy kit (Qiagen, Courta-
boeuf, France), following the instructions of the manufacturer. The
yield of total RNA averaged 1.3 Wg/well from a 6-well culture plate,
corresponding to approximately 250 000 myoblasts per well at con£u-
ence, before induction of the di¡erentiation process.
The absolute mRNA concentration of p85KPI-3K was determined
using the reverse transcription-competitive polymerase chain reaction
(RT-cPCR) assay as previously described [23]. The RT reaction was
performed with 0.1 Wg of total RNA in the presence of the speci¢c
antisense primer and a thermostable reverse transcriptase enzyme to
warrant optimal synthesis of ¢rst strand cDNA [24]. Cy-5 5P-end
labeled sense primer was used during the cPCR to generate £uorescent
PCR products that were analyzed using an automated laser £uores-
cence DNA sequencer (ALFexpress, Pharmacia, Uppsala, Sweden) in
4% denaturing polyacrylamide gels.
2.4. Quanti¢cation of p85KPI-3K protein by Western blotting
Myotubes were homogenized in a phosphate-bu¡ered saline (PBS)
lysis bu¡er containing 1% Nonidet P-40 (Sigma), 0.5% sodium des-
oxycholate (Sigma), 0.1% SDS (Sigma) and supplemented with a
freshly prepared cocktail of protease inhibitors (ICN Pharmaceuticals,
Orsay, France). Proteins (5 Wg) were separated by SDS^PAGE and
transferred to polyvinylidine di£uoride (PVDF) membrane (Millipore,
France). Quanti¢cation of p85KPI-3K protein amount was performed
as previously described [23], using a rabbit polyclonal antibody (Up-
state Biotechnology, New York, USA).
2.5. Determination of PI3-kinase activity
Myotubes were homogenized in a lysis bu¡er (140 mM NaCl, 20
mM Tris^HCl pH 7.4, 10 mM EDTA, 100 mM NaF, 2 mM vanadate,
10 mM pyrophosphate, 1% Nonidet P-40) supplemented with a
freshly prepared cocktail of protease inhibitors. Immunoprecipitation
with the antibody of the p85KPI-3K (Upstate Biotechnology) and
determination of PI3-kinase activity on the immunoprecipitate were
performed as previously described [20].
3. Results
At the mRNA level, PPARQ was expressed at the lowest
level among the members of the PPAR family, both in human
skeletal muscle and in primary muscle cells in culture (Fig. 1).
Only PPARQ1 mRNA was measurable in muscle biopsies or
in di¡erentiated myotubes. The mRNA of PPARQ2, the adi-
pocyte-speci¢c isoform, was not detectable (data not shown).
There was no di¡erence in PPARQ mRNA levels in di¡eren-
tiated myotubes and in muscle biopsies. The cultured cells
were however characterized by modi¢cations in the mRNA
expression of the other PPARs (Fig. 1). PPARK mRNA levels
were slightly lower in myotubes than in muscle biopsies, and
PPARL expression was about 4-fold higher in the cultured
cells.
We have previously shown that treatment of human adipo-
cytes with Rosiglitazone for 6 h resulted in a signi¢cant in-
duction of p85KPI-3K mRNA expression. Fig. 2 shows that
such e¡ect did not take place in human myotubes. Addition of
15-deoxy-v12;14 prostaglandin J2 (15vPGJ2), a proposed nat-
ural ligand of PPARQ, also did not modify the mRNA ex-
pression of p85KPI-3K (Fig. 2). It should be added that the
mRNA levels of p85KPI-3K were not a¡ected after 24 h of
incubation with either Rosiglitazone or 15vPGJ2 (data not
shown). Activation of PPARL with L-165041, also did not
modify signi¢cantly the mRNA levels of p85KPI-3K in human
myotubes (Fig. 2). In contrast, activation of PPARK by Wy-
14643 produced an about 2-fold increase in p85KPI-3K
mRNA levels (87 þ 36%, P = 0.03) after 6 h of incubation
(Fig. 2).
To verify whether the induction of p85KPI-3K mRNA lev-
els was mediated by the heterodimer PPARK/RXR, we inves-
tigated the e¡ect of 9-cis-RA alone and in combination with
Wy-14643. As shown in Fig. 3, the treatment of myotubes for
6 h with 9-cis-RA alone signi¢cantly increased the concentra-
tion of p85KPI-3K mRNA (121 þ 24%, P6 0.001). The com-
Fig. 1. Comparison of PPARK, L and Q mRNA expression between
human skeletal muscle biopsies and primary cultures of muscle cells.
The concentrations of the di¡erent PPAR mRNAs were determined
in muscle (vastus lateralis) biopsies (open boxes, n = 6) and in di¡er-
entiated myotubes (black boxes, n = 5) obtained from healthy sub-
jects using the RT-cPCR assay previously described and validated
[6]. The vastus lateralis muscle biopsies were obtained from subjects
participating in a separated study [29]. Data are presented as the
mean þ S.E.M.
Fig. 2. E¡ect of di¡erent PPAR activators on p85KPI-3K mRNA
levels in human myotubes. The mRNA level of p85KPI-3K was de-
termined after 6 h of incubation with 1036 M of the indicated acti-
vators. The ¢nal concentration of DMSO (vehicle) was kept at 0.1%
in all conditions. The ¢gure shows the mean þ S.E.M. for ¢ve to
eight di¡erent experiments involving ¢ve independent preparations
of muscle cells. *P6 0.05 vs. vehicle.
FEBS 25084 30-7-01
J. Rieusset et al./FEBS Letters 502 (2001) 98^102 99
bination of Wy-14643 and 9-cis-RA further increased p85KPI-
3K mRNA levels (285 þ 72%, P6 0.001). The change induced
by the combination of the two activators was signi¢cantly
higher (P6 0.03) than the change obtained with Wy-14643
or 9-cis-RA alone, indicating a potentiation of the e¡ect
when the two partners of the PPARK/RXR heterodimer
were activated. Interestingly, a combination of Rosiglitazone
and 9-cis-RA also induced an increase in p85KPI-3K mRNA
levels (107 þ 23%, n = 6), but the magnitude of the e¡ect was
similar to what was obtained with 9-cis-RA alone (121 þ 24%).
The lack of potentiation when Rosiglitazone and 9-cis-RA
were used in combination further suggested that PPARQ was
not involved in the regulation of p85KPI-3K expression in
human muscle cells.
The observed up-regulation of p85KPI-3K mRNA by
PPARK/RXR heterodimer was followed by a signi¢cant in-
crease in p85KPI-3K protein levels after 12 h of incubation
(Fig. 4). However, when the myotubes were incubated with
Wy-14643 alone, the amount of p85KPI-3K protein was not
signi¢cantly a¡ected while treatment with 9-cis-RA promoted
an about 2-fold increase (1.8 þ 0.1-fold, P6 0.002, n = 4). The
combination of Wy-14643 and 9-cis-RA increased p85KPI-3K
protein to a slightly, but signi¢cant, higher level (1.9 þ 0.1,
P6 0.002 vs. vehicle or Wy-14643 and P6 0.05 vs. 9-cis-RA
alone).
The e¡ect of Wy-14643 and 9-cis-RA on total PI3-kinase
activity was determined in anti-p85KPI-3K immunoprecipi-
tates. Fig. 6 represents insulin stimulation (10 min) of PI3-
kinase activity in three independent cell preparations after 12
h of incubation with Wy-14643 and 9-cis-RA. Treatment with
the activators did not modify the basal PI3-kinase activity,
but dramatically increased the e¡ect of insulin (11 þ 2.8 vs.
3 þ 0.8-fold increase over basal with vs. without treatment
for 12 h with Wy-14643 and 9-cis-RA) (Fig. 5). These data
demonstrate thus that the increase in p85KPI-3K expression
Fig. 3. E¡ect of the PPARK/RXR heterodimer activation on
p85KPI-3K mRNA levels. The mRNA levels of p85KPI-3K were de-
termined after 6 h of incubation with 1036 M of the indicated acti-
vators. The ¢nal concentration of DMSO (vehicle) was kept at 0.1%
in all conditions. The ¢gure shows the mean þ S.E.M. for ¢ve inde-
pendent preparations of muscle cells. *P6 0.05 vs. vehicle and
$P6 0.05 vs. Wy-14643 or 9-cis-RA alone.
Fig. 4. E¡ect of PPARK/RXR heterodimer activation on p85KPI-
3K protein levels in human myotubes. Western blots of p85KPI-3K
were performed in di¡erentiated myotubes incubated for 12 h with
1036 M of the indicated activators. The ¢gure shows a representa-
tive experiment that was reproduced in four preparations of human
myotubes.
Fig. 5. E¡ect of PPARK/RXR heterodimer activation on insulin-in-
duced PI3-kinase activity. Myotubes were incubated for 12 h with
1036 M of Wy-14643 and 9-cis-RA, and PI3-kinase activity was
measured in anti-p85KPI-3K immunoprecipitates before and after 10
min of stimulation with insulin (1037 M). The ¢gure shows the
mean þ S.E.M. for three independent preparations of human myo-
tubes and the results are presented as arbitrary units taking the
basal PI3-kinase activity of the untreated cells as 1 unit.
Fig. 6. E¡ect of actinomycin D and cycloheximide on the induction
of p85KPI-3K mRNA. The upper panel shows that addition of acti-
nomycin D (1036 M) completely prevented the induction of p85KPI-
3K by Wy-14643 and 9-cis-RA (incubation time = 6 h). In contrast,
the lower panel shows that cycloheximide (1036 M) did not alter
the e¡ect of Wy-14643 and 9-cis-RA. Data are presented as means
þ S.E.M. for four di¡erent experiments.
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(mRNA and protein levels) was associated with a marked
potentiation of insulin signaling in human muscle cells.
Fig. 6 shows that the e¡ect of Wy-14643 and 9-cis-RA on
the mRNA expression of p85KPI-3K could be completely pre-
vented by actinomycin D, a potent inhibitor of RNA poly-
merase II, suggesting that the PPARK/RXR heterodimer af-
fects the transcriptional regulation of p85KPI-3K gene.
Furthermore, the rise in p85KPI-3K mRNA in response to
Wy-14643 and 9-cis-RA was not a¡ected by cycloheximide
(Fig. 6), indicating that protein synthesis is not required in
the mechanism of action of these molecules on p85KPI-3K
gene. These results suggested that the PPARK/RXR hetero-
dimer directly controls the expression of the p85KPI-3K gene
at the transcriptional level in human muscle cells in culture.
4. Discussion
We have recently reported that activation of PPARQ by
Rosiglitazone increases the expression of p85KPI-3K in hu-
man isolated adipocytes without a¡ecting insulin receptor,
insulin receptor substrate (IRS)-1 or the p110K and L catalytic
subunits of PI-3K [19,20]. This speci¢c induction of p85KPI-
3K by Rosiglitazone was ampli¢ed in the presence of a RXR
activator, strongly suggesting that the gene encoding p85KPI-
3K is a target of the heterodimer PPARQ/RXR in human
adipocytes. We found, in the present work, that this regula-
tion of p85KPI-3K expression by thiazolidinediones did not
take place in human di¡erentiated muscle cells. The activation
of PPARQ (with Rosiglitazone or with 15vPGJ2) did not
modify the mRNA expression of p85KPI-3K. This marked
di¡erence from what we have previously observed in human
adipocytes could be a consequence of the very low expression
level of PPARQ in muscle compared to the fat cells. Such
di¡erence in the response to thiazolidinediones between adi-
pocytes and muscle cells has been already observed in the case
of the uncoupling protein 2 (UCP-2) gene, the expression of
which is up-regulated in human adipocytes [19] and una¡ected
in human myotubes [25]. Similar tissue-speci¢c e¡ects have
been also reported for the genes encoding the fatty acid trans-
porter protein-1 (FATP-1) and the lipoprotein lipase in ro-
dents adipose and muscle cell lines [26,27]. It is likely that the
very low level of PPARQ in muscle cells, and, in contrast, its
very high level in adipocytes may explain these observations
and the preferential e¡ect of the thiazolidinediones in fat cells.
In contrast to PPARQ activators, the expression of p85KPI-
3K was signi¢cantly increased by Wy-14643 and 9-cis-RA in
myotubes. These results indicated that p85KPI-3K gene is
preferentially under the transcriptional control of the
PPARK/RXR rather than the PPARQ/RXR heterodimer in
human muscle cells. In rat skeletal muscle, FATP-1 mRNA
expression is also up-regulated by activation of PPARK with
feno¢brate [26]. Because PPARK is expressed at higher level
than PPARQ in muscle cells, one could assume that the tissue-
speci¢c regulation of these genes may depend on the relative
abundance of the PPARs. However, in human myotubes,
PPARL is more expressed than PPARK and its activation
did not change the mRNA expression of p85KPI-3K. Further-
more, we have recently shown that UCP-2 gene expression is
increased by activation of PPARL and not by activation of
PPARK in human myotubes [25]. Therefore, all these results
suggest that, in addition to the relative abundance of the
di¡erent PPARs, speci¢c regulatory mechanisms are involved
in the transcriptional regulation of these genes. Studies of
their promoters are required to verify whether the same
PPREs mediate the tissue-speci¢c e¡ects of the di¡erent
PPARs or whether di¡erent regions of the promoters are in-
volved in a tissue-dependent manner.
The product of the p85KPI-3K gene is an adapter protein
that links the catalytic subunit of PI-3K to upstream signaling
molecules (such as the IRSs), playing thus a major role in the
intracellular action of insulin [21]. We found that insulin-in-
duced PI3-kinase activity is markedly induced in cells treated
with the PPARK/RXR agonists. Activation of the PI-3K
pathway is required for a variety of insulin e¡ects, including
the regulation of glucose uptake and glycogen synthesis in
skeletal muscle [21]. These metabolic pathways are altered in
pathologies characterized by insulin resistance [22], and defec-
tive expression and activation of PI-3K have been reported in
subjects with type-2 diabetes or obesity [28,29]. Activation of
PPARK with ¢brates is mainly known to lower plasma lipid
concentrations [1,2]. In addition to this e¡ect, PPARK activa-
tors can also improve insulin sensitivity both in type 2 diabetic
patients [30] and in rodent models of insulin resistance [31].
Therefore, the identi¢cation of p85KPI-3K as a possible target
gene of PPARK in muscle could explain, at least in part, the
bene¢cial e¡ect of ¢brates on insulin action.
Another interesting results of this study is the demonstra-
tion that 9-cis-RA was able to increase p85KPI-3K mRNA
and protein expression in human muscle cells. It appeared
therefore that activation of RXR can transactivate p85KPI-
3K gene, either through a PPARK/RXR heterodimer or
through a complex involving another partner of RXR. This
result suggests that treatment with RXR activators may a¡ect
insulin sensitivity. In agreement with this hypothesis, a speci¢c
agonist of RXR has been recently shown to improve insulin
action in a model of insulin-resistant mice [32].
In conclusion, the present study and our previous work [20]
indicate that p85KPI-3K gene expression is regulated in a
tissue-speci¢c manner by PPARK activation in muscle and
by PPARQ activation in adipose tissue. Similar complementa-
ry actions of PPARK and Q activators have been previously
observed in rodents concerning genes involved in lipid metab-
olism [26,27,33]. We found that these dual e¡ects can also
occur in human tissues for a key gene of insulin action. If
this tissue-selective regulation of p85KPI-3K also results in
an improved insulin sensitivity in vivo, our observations sug-
gest that the development of drugs with a dual action on both
PPARQ and PPARK may be of interest for the treatment of
pathologies characterized by insulin resistance like type 2 dia-
betes mellitus.
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